Danish-Swedish Launch Event for the Innovative Medicines Initiative (IMI2)
Research and funding opportunities for SMEs, Research Institutions, Hospitals and other stakeholders in the area of medicine development.
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private partnership in life science. It is jointly run and funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve the process of developing new drugs and treatments by supporting cooperation in research and development.
Launched in 2008, the initiative is now being renewed under the EU’s framework programme Horizon 2020. IMI2 will run for 10 years with a budget of approximately €3 billion euro.
The IMI2 launch event in Copenhagen is an opportunity for a wide range of stakeholders to learn about the research priorities of IMI2 and the calls to be launched in 2014. The event will also highlight the experiences and learnings of Swedish and Danish IMI project participants from both industry and academia.
The event is organised by VINNOVA & the Danish Agency for Science, Technology and Innovation and hosted by the Medicon Valley Alliance
Date: August 28, 2014
Time: 11:30 – 16:00
Venue: Edvard Thomsens Vej 14, 2300 København S
Language: English
Registration on come first, first served basis.
SIGN UP HERE
Attendance is free of charge, but we have a late cancellation * /no-show fee at DKK 500 ex VAT.
Registrations ends at August 22, 2014.
* If you cancel after the registration ends, it is considered late cancellation.
Program
| 11.30-12.00 | Registration and lunch |
| 12. 00-12.15 | Welcome/ VINNOVA & Danish Agency for Science, Technology and Innovation |
| 12.15 – 13.15 | Hugh Laverty, Senior Scientific Project Manager, IMI Executive Office
|
| 13. 15 – 13 45 | Magali Poinot, Legal Manager, IMI Executive Office · Rules of engagement in IMI2 · Intellectual Property in IMI 2 |
| 13.45- 14.15 | Coffee break |
| 14.15 – 14.35 | Joining IMI – The academic experience: Leif Groop , University of Lund. SUMMIT, Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools |
| 14.35 – 14.55 | Joining IMI – the SME perspective: Arsalan Kharazmi, CEO Biomonitor A/S ABIRISK project (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk) |
| 14. 55 – 15.15 | IMI & patient involvement in Medicine R&D: Niels Westergaard, Science & Innovation Network Manager, Biopeople EUPATI, European Patients‘ Academy on Therapeutic Innovation |
| 15.15 – 15.30 | Introduction to IMI partnering tools, Jan Skriwanek, National Contact Point Life Sciences German Aerospace Center. |
| 15.30 – 16.00 | Closing remarks, wine and networking |